Lomustine (CCNU)
General information
Class/mechanism: Nitrosourea, alkylates DNA and RNA and may inhibit certain key enzymatic reactions by carbamoylation of amino acids in proteins.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Lomustine (Ceenu) patient drug information (Chemocare)[3]
- Lomustine (Ceenu) patient drug information (UpToDate)[4]
Also known as
Also known as CCNU.
- In 10/2013, Bristol-Myers Squibb discontinued production of their Lomustine brand name, CeeNu.[5] Lomustine will be supplied as CCNU by NextSource Biotechnology.[6]
References
- ↑ 1.0 1.1 Lomustine (Ceenu) package insert
- ↑ Lomustine (Ceenu) package insert (locally hosted backup)
- ↑ Lomustine (Ceenu) patient drug information (Chemocare)
- ↑ Lomustine (Ceenu) patient drug information (UpToDate)
- ↑ Discontinued drug bulletin: Lomustine capsules (American Society of Health-System Pharmacists)
- ↑ NextSource Biotechnology Lomustine (CCNU) update